in ventilation—perfusion heterogeneity, as seen in patients treated with a high dose of intravenous epoprostenol in whom IPS and severe hypoxaemia occurred. In these cases, an accurate diagnosis and drug down-titration or discontinuation allowed a rapid recovery of the symptoms. In conclusion, sildenafil may be associated with development of IPS and hypoxaemia in PAH patients. In these cases, an SC-TTE should be performed in order to disclose previously undiagnosed IPS.

Pablo F Castro,1 Douglas Greig,1 Hugo E Verdejo,1 Iván Godoy,1 Samuel Córdova,1 Marcela P Ferrada,1 Robert C Bourge2

1Department of Cardiovascular Diseases, Coronary Care Unit, Pontificia Universidad Católica de Chile, Santiago de Chile, Chile; 2Division of Cardiovascular Disease, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA

Correspondence to Pablo F Castro, Department of Cardiovascular Diseases, Coronary Care Unit, Pontificia Universidad Católica de Chile, Marcoleta 367, 7 floor, Santiago de Chile, Chile; pcastro@med.puc.cl

Institution at which the work was performed: Pontificia Universidad Católica de Chile, Santiago de Chile, Chile.

Competing interests None.

Patient consent Obtained.

Ethics approval This study was conducted with the approval of the Pontificia Universidad Católica de Chile.

Provenance and peer review Not commissioned; externally peer reviewed.

Accepted 6 January 2011
Published Online First 2 February 2011
doi:10.1136/thx.2010.156711

REFERENCES

Risk stratification in pulmonary embolism: an algorithmic tool approach

It is with much interest we read the article by Jiménez et al1 and the accompanying editorial2 focusing on patients with symptomatic pulmonary thromboembolism (PTE) but who are normotensive at presentation, it reminds us that work still needs to be undertaken for the 95% of patients (including the 15% with submassive disease) who remain haemodynamically stable and excluded from thrombolysis, if current guidelines are followed.3 Anecdotally, with the increased use of CT pulmonary angiography, clinicians more readily visualise thrombus burden and, despite the lack of scientific evidence, consider thrombolytic therapy ahead of heparin even with submassive PTE. Although the mortality benefits from thrombolysis in this group are debatable, it does help improve the right ventricular function more rapidly than anti-coagulation alone, reducing complications of chronic thromboembolic pulmonary hypertension.4 The paper by Jiménez1 recognises and evaluates the prognostic tools currently being used in risk analysis, reminding us that the use of a two-test strategy has a higher specificity and positive predictive value of pulmonary embolism-related death than any single test itself, whether using cardiac biomarkers such as troponin (cTnI/T), cardiac ECHO or lower extremity complete compression ultrasound. Importantly, it also clarifies that although there is a trend to better evaluation with all three tests used together, the difference comparing a two-test approach with a three-test approach is not statistically significant.
In an attempt to identify patients who can be appropriately managed in a semi-outpatient (after day 2) ambulatory manner and, at the other extreme, patients for active outpatient (after day 2) ambulatory manner can be appropriately managed in a semi-

**Figure 1** Pulmonary embolism (PE) protocol. COPD, chronic obstructive pulmonary disease; HR, heart rate; PESI, pulmonary embolism severity index; RR, respiratory rate; SaO\(_2\), saturation of oxygen; SBP, systolic blood pressure; T, temperature.

**Competing interests** None.

**Provenance and peer review** Not commissioned; not externally peer reviewed.

Accepted 2 February 2011


**REFERENCES**


**Authors’ response**

We thank Dr Ahmad and colleagues for their thoughtful comments. Haemodynamic instability has significant prognostic implications for patients diagnosed as having acute pulmonary embolism (PE), and guidelines generally recommend consideration of treatment with thrombolytic agents. At the other end of the spectrum, different studies suggest that risk stratification models (particularly the Pulmonary Embolism Severity Index (PESI) and the simplified PESI) may accurately identify patients at low risk of death within the first 3 months after the diagnosis of PE. One study found that the addition of troponin testing to the PESI did not increase the prognostic value of the PESI for the identification of low-risk patients who might benefit from a shortened hospital stay or outpatient therapy. Although recent data suggest that the use of a highly sensitive troponin T (hsTnT) assay may improve the risk stratification of PE, future studies should address the usefulness of hsTnT and risk stratification models, alone or in combination, for identifying low-risk patients who can be discharged early from the hospital and treated as outpatients. Our recent study adds to the body of evidence that a combination of cardiac biomarkers, echocardiographic findings and lower limb ultrasound testing are useful for fine-tuning risk stratification in the subgroup of intermediate-risk patients with acute symptomatic PE.

David Jiménez, on behalf of all coauthors

Respiratory Department, Ramón y Cajal Hospital, IRYCIS, Madrid, Spain

Correspondence to David Jiménez, Ramón y Cajal Hospital, Colmenar Road, Madrid 28034, Spain; dje_69_98@yahoo.com

Competing interests None.

Provenance and peer review Not commissioned; not externally peer reviewed.

Accepted 2 February 2011

Published Online First 23 February 2011


**REFERENCES**


Risk stratification in pulmonary embolism: an algorithmic tool approach

N Ahmad, K Srinivasan and H Moudgil

Thorax 2011 66: 1098-1099 originally published online February 23, 2011
doi: 10.1136/thx.2011.159699

Updated information and services can be found at:
http://thorax.bmj.com/content/66/12/1098

These include:

References
This article cites 5 articles, 3 of which you can access for free at:
http://thorax.bmj.com/content/66/12/1098#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/